Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen report shared beneficial ownership of 2,290,023 shares of Beta Bionics common stock, representing 5.2% as of February 20, 2026.
The filing states these Reporting Persons hold the shares through Point72 Associates, LLC, with shared voting and dispositive power of 2,290,023 shares. The cover page figures are reported as of the close of business on February 20, 2026.
Beta Bionics, Inc. reported sharp growth for the fourth quarter and full year 2025 while remaining loss-making. Full-year net sales reached $100.3 million, up 54% from $65.1 million, driven by both Durable Medical Equipment and Pharmacy Benefit Plan channels. Fourth-quarter net sales were $32.1 million, up 57% year over year.
Gross margin improved modestly to 55.4% for 2025. The installed customer base rose to 35,011 users, up 129%, with 19,713 new patient starts, a 52% increase. A high-20s percentage of 2025 new patient starts and a low-30s percentage in the fourth quarter were reimbursed through the PBP channel, showing rapid pharmacy channel expansion.
The company still posted a full-year net loss of $73.2 million, or $1.81 per share, with adjusted EBITDA of negative $52.8 million. Beta Bionics ended 2025 with $264.7 million in cash, cash equivalents, and investments and issued 2026 guidance for revenue of approximately $130 million to $135 million and gross margin of 55.5% to 57.5%.
Beta Bionics, Inc. (BBNX) had a significant shareholder position reported by RTW Investments, LP and its managing partner, Roderick Wong, M.D. The reporting group beneficially owns 2,500,000 shares of common stock, representing 5.7% of the company.
This ownership percentage is based on 44,024,631 shares outstanding as of October 24, 2025, as cited from the company’s Form 10-Q. All 2.5 million shares are held by RTW-managed funds, with RTW and Dr. Wong having shared voting and investment power and no sole voting or dispositive power.
The securities are certified as being held in the ordinary course of business, without the purpose or effect of changing or influencing control of Beta Bionics. The RTW funds are entitled to receive dividends and proceeds from any sale of these shares.
Soleus Capital-affiliated funds and Guy Levy filed an amended Schedule 13G reporting their beneficial ownership of Beta Bionics, Inc. common stock. As of the share count in the issuer’s Form 10-Q, Soleus Capital Management, L.P. and Soleus GP, LLC each report beneficial ownership of 2,503,778 shares, or 5.7% of the company’s common stock. Guy Levy reports beneficial ownership of 2,534,565 shares, or 5.8%, including 30,787 shares over which he has sole voting and dispositive power and the balance on a shared basis through the Soleus funds. Several Soleus entities and Mr. Levy expressly disclaim beneficial ownership of shares held by the funds except for purposes of Section 13(d), and they certify the holdings are not for the purpose of changing or influencing control of Beta Bionics.
Wellington Hadley Harbor Aggregator IV, L.P. reports that it no longer beneficially owns any shares of Beta Bionics, Inc. common stock. The amended Schedule 13G shows 0 shares beneficially owned, representing 0.0% of the class, with no sole or shared voting or dispositive power.
The filing notes that any securities previously held were not acquired or held for the purpose of changing or influencing control of Beta Bionics. Wellington certifies this change in ownership status as of 12/31/2025, formally confirming it is now below the 5% reporting threshold.
Beta Bionics, Inc. (BBNX) received an amended Schedule 13G from Wellington Management Group LLP and related entities showing they no longer hold a reportable stake in the company. As of 12/31/2025, Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP each report 0.00 shares of Beta Bionics common stock, representing 0.0% of the outstanding class, with no sole or shared voting or dispositive power.
The filing explains that any Beta Bionics shares covered by this schedule are owned of record by clients of various Wellington investment advisers, and no single client is known to hold more than five percent of the common stock. Wellington also certifies that any securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Beta Bionics.
Beta Bionics, Inc. received an updated Schedule 13G/A from Farallon-affiliated investors and Zone Healthcare Holdings, LLC. The filing reports Zone Healthcare Holdings and Farallon Capital Management, L.L.C. each beneficially owning 3,277,220 common shares, or 7.4% of the company.
Farallon’s individual reporting persons, including multiple senior investment professionals, are each reported as beneficial owners of 4,379,920 shares, representing 9.9% of the common stock. The amendment records governance changes: effective December 31, 2025, Richard B. Fried, Rajiv A. Patel, and William Seybold ceased to be beneficial owners, while effective January 1, 2026, Avner A. Husen became a deemed beneficial owner through his new management roles.
The group files under Rule 13d-1(c) and certifies the shares were not acquired to change or influence control of Beta Bionics.
Beta Bionics reported that it received a warning letter from the U.S. FDA on January 29, 2026 following an inspection of its Irvine, California facility conducted in June 2025. The FDA cited deficiencies in the company’s responses to a prior Form 483 and highlighted non-conformities in its quality system, medical device reporting, and correction and removal processes.
The letter does not currently limit Beta Bionics’ ability to manufacture, market, or distribute products, or to seek FDA 510(k) clearance for new products. The company has begun corrective actions, is preparing a written response, and plans ongoing updates to the FDA, but notes that additional regulatory action is possible until issues are resolved. Beta Bionics states it does not expect this warning letter to materially affect its previously disclosed guidance to launch commercialization of Mint by the end of 2027.
Beta Bionics, Inc. director Michel Gerard reported receiving an award of 3,997 shares of common stock on 01/13/2026. The filing shows this as an automatic acquisition at a price of $0 per share, representing a restricted stock unit grant under the company’s 2025 Equity Incentive Plan. Following this award, Gerard beneficially owns 16,544 shares of Beta Bionics common stock in direct form.
Beta Bionics, Inc. director Sean Carney reported a stock-based award. On 01/13/2026, he acquired 3,997 shares of common stock at a price of $0, described as a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. After this grant, he beneficially owned 15,244 shares of Beta Bionics common stock, held directly.